Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma

NCT01345019 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01345019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01345019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 17, 2012
Completion date
March 29, 2019
Enrollment
1,718 (actual)
Sites
309

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, cancer, hematologic malignancies, multiple myeloma, multiple myeloma bone lesions, oncology